Jennifer H. Roscetti
Jennifer Roscetti practices patent litigation in a range of chemical and pharmaceutical fields before U.S. district courts and the U.S. International Trade Commission (ITC). She has particular experience in representing pharmaceutical patent holders in litigations arising under the Hatch-Waxman Act. Ms. Roscetti's experience includes arguing a Markman hearing; examining and cross-examining fact and expert witnesses at trial; arguing discovery and scheduling motions; handling all aspects of trial preparation including patent litigation strategy development; working with expert witnesses; and conducting and defending key witness depositions.
Prior to joining Finnegan, Ms. Roscetti worked as a design engineer for ExxonMobil Chemical Company while she attended law school. Before law school, she worked as a process engineer for E.I. du Pont de Nemours and Company in the Teflon® division. Ms. Roscetti also engaged in research on anti-cancer drugs in the College of Pharmacy at the University of Kentucky.
- Grünenthal GmbH et al. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y.). Representing Grünenthal in Hatch-Waxman litigations relating to abuse-deterrent formulations of OxyContin® and Opana®.
- Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc. (D. Del.). Represented Pronova in Hatch-Waxman litigation relating to drug Lovaza®, resulting in judgment of patent infringement, validity, and enforceability in Pronova's favor.
- Served on the team representing Tate & Lyle in an ITC investigation involving methods of manufacturing sucralose, and artificial sweetener, including examining and cross-examining fact and expert witnesses.
- Ariad v. Eli Lily and Co. (D. Mass.). Member of bench trial team that represented Lilly, sued for infringing patent on NF- ĸB inhibition. Federal Circuit issued landmark en banc opinion on the written description requirement and reversed adverse trial court judgment.
- Eli Lily and Co. v. Teva Pharmaceuticals USA, Inc. (S.D. Ind.). Assisted in representing Lilly in action to prevent generic competition with respect to osteoporosis drug EVISTA®. Two of three patent families in suit found valid and infringed.
- Adjunct professor in Patent Law and Advanced Topics in Patent Policy at Howard University School of Law, 2012-present.
- American Bar Association
- Maryland State Bar
- American Intellectual Property Law Association
- Women's Bar Association of the District of Columbia
- ITC Trial Lawyers Association
- American Institute of Chemical Engineers